ESMO 2023 Archives

Avons-nous déCODEs les mutations KRAS G12C des adénocarcinomes (ADK) coliques métastatiques? Filippo Pietrantonio, Milan, LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
FOLFOXIRI + beva dans le cancer colique droit métastatique RAS/RAF muté : change-t-on réellement la fin de l’histoire ? Cornelis Punt, Utrecht, Pays Bas, LBA27 - First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group,
Tumeurs colorectales métastatiques RAS/BRAF sauvages : faut-il intensifier le traitement ? Thibault Mazard, Montpellier, Panitumumab + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer patients with RAS/BRAF wild-type tumor status from circulating DNA: First résults of the randomised phase II PANIRINOX-UCGI28 study
Rechercher une mutation KRAS et BRAFV600E en situation adjuvante: belle IDEA ! Julien Taieb, Paris, 553O - Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials
Zolbetuximab + FOLFOX en première ligne du cancer gastrique avancé exprimant la claudine 18.2 : essai transformé pour l’étude SPOTLIGHT Jaffer A Ajani, Houston, USA, , LBA82 - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma,
Match nul entre le FOLFIRINOX et la radiochimiothérapie en preopératoire dans le cancer du pancréas localisé (PREOPANC-2). Bas Groot Koerkamp, Rotterdam, Pays Bas, , LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial,
Nivolumab + relatlimab en néodjuvant du cancer colorectal dMMR localisé : NICHE-3 encore plus fort que NICHE-2 ? Yara Verschoor, Amsterdam, Pays Bas, LBA31 - Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study,
Allons nous être CONVERTis à la chimiothérapie seule pour les adénocarcinomes (ADK) rectaux localement avancés ? P.R Ding, Shantou, LBA26 - Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial,
ASCOLT, doit-on dégainer l’aspirine après résection d’un cancer colorectal? John Chia, Singapore, , LBA29 - Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial,
La révolution de l’immunothérapie : les IPP s’invitent pour gâcher la fête Lawson Eng, Toronto, Canada, 2033MO - The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study,
FLOT ou FOLFOX pour les adénocarcinomes gastriques non résécables: jamais 2 sans 3 ! Aziz Zaanan, Paris, LBA77 - 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX- PRODIGE 51): A randomized phase III trial sponsored by the FFCD,
Une nouvelle option après progression des TNE ! Jennifer Chan, Boston LBA53 - Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Quelle chimio dans les TNE avancées ? le statut MGMT pour trancher Thomas Walter, Lyon, France, , LBA54 - Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network,
L’immunothérapie dans les cancers localement avancés du rectum : l’UNION fait-elle la la force ? Z.Lin, Wuhan, T. Zhang, Wuhan, LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)
Inhibiteur de KRAS G12C + anti EGFR : une nouvelle molécule s’invite dans la course Rui-Hua Xu Guangzhou, China, , 550O - Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study,
L’immunothérapie en péri-opératoire du cancer gastrique localisé : un sommet qui résiste ? Yelena Janjigian, New York, USA, , LBA73 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study,
Peut-on se passer de la chirurgie dans le cancer de l’oesophage localement avancé? Berend J. Van der Wilk, Rotterdam, LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial,
« Cancers gastriques avancés non résécables HER2+ avec CPS ≥1 : Pembro ou Trastu ? Les deux mon capitaine ! » Yelena Janjigian, New York, , 1511O - Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study